Avalo Therapeutics, Inc.

What they do

Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), is a humanized anti-IL-1 monoclonal antibody currently in a Phase 2 clinical trial (LOTUS) for hidradenitis suppurativa (HS). The company also has a preclinical candidate, AVTX-010, a long-acting next-generation anti-IL-1 antibody. Avalo has no approved products and generates no product revenue.

Revenue drivers

• Product sales — No approved products; annual revenue has been minimal or zero in recent years (2025: $59,000; 2024: $441,000), with no quarterly revenue reported in some periods.
• Out-licensing and asset sales — Historically funded operations through out-licensing transactions and sales of assets, but no specific out-licensing revenue is disclosed in the current filings.

Recent performance

For the second quarter of 2026, Avalo reported a net loss of $36.4 million, an increase of $15.6 million from the second quarter of 2025. R&D expenses rose to $23.4 million (up $9.3 million), driven by a $10.0 million development milestone and HS development costs. G&A expenses were $8.1 million (up $2.9 million) mainly due to stock-based compensation. As of June 30, 2026, cash, cash equivalents and investments totaled $472.2 million, while total assets were $490.8 million, total liabilities $42.1 million, and shareholder equity $448.7 million.

Strategy

Avalo is prioritizing completion of the Phase 2 LOTUS trial in HS and planning for a Phase 3 registrational program, with initiation targeted for the first half of 2027. The company is expanding its pipeline with AVTX-010, a long-acting anti-IL-1 antibody, and plans an IND submission in the first half of 2027. Management also aims to acquire or in-license complementary targeted preclinical and clinical stage compounds for immune-mediated inflammatory diseases, and opportunistically out-license rights to compounds, indications or geographies.

Risks

• Clinical trial failure — If abdakibart's Phase 3 trials fail to demonstrate safety and efficacy, the company may be unable to obtain regulatory approval and its business could be materially harmed.
• Dependence on single lead candidate — Avalo's focus and reliance on abdakibart (AVTX-009) increases risk; any delay or failure in its development could significantly impact the company.
• Capital needs — The company expects to require additional capital in the future to fund operations and advancement of its pipeline; if not available on acceptable terms, it may delay, limit or terminate product development efforts or cease operations.
• Reliance on third parties — Clinical trials are conducted by third parties; their failure to meet contractual obligations or deadlines could hinder timely commercialization or regulatory approval.

Outlook

Management expects to report topline data from the Phase 2 LOTUS trial in the second quarter of 2026 (already reported positive as of the latest 10-Q), and plans to initiate a registrational Phase 3 program in HS in the first half of 2027. The company also plans an IND submission for AVTX-010 in the first half of 2027. Based on current operating plans, Avalo expects existing cash, cash equivalents and investments to fund operations into 2029.